Role of Systemic Therapy in TACE-Eligible Patients
The panelist discusses how for patients initially eligible for embolization, systemic therapy may be combined with transarterial chemoembolization (TACE) upfront for high-risk disease (ie, large tumor burden, elevated AFP) or reserved for progression after regional therapy in lower-risk cases. Treatment decisions should be individualized based on tumor characteristics, liver function, and patient preferences.
Video Player is loading.
Video content above is prompted by the following:
- What are your perspectives on when and how systemic therapy fits into the treatment paradigm for patients who are initially eligible for embolization?
- Should systemic therapy be considered upfront in combination with eg, TACE or reserved for progression after regional therapy?
- Review and discuss recent evidence from the EMERALD-1 and LEAP-012 trials.
- What are the clinical implications of these data?
- What patient/nonpatient specific factors would influence these treatment decisions?
Recent Videos
COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
Clinical Impact of COCOON: Advancing Dermatologic AE Management
Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease
